方正证券承销保荐有限责任公司 （天职业字[2022]9819 号）。募集资金到账后，已全部存放于开设的募集资金专 项账户内，公司与保荐机构、存放募集资金的商业银行签署了《募集资金专户存 储三方监管协议》。 二、募集资金使用情况 根据公司《首次公开发行股票并在科创板上市招股说明书》披露，公司首次 公开发行股票募投项目如下： | 序号 | 项目名称 | 募集资金拟投入 金额（万元） | 项目进度 | | --- | --- | --- | --- | | 1 | 特效新药及创新技术研发项目 | 20,000.00 | 实施中 | | 2 | 上海赛伦生物技术股份有限公司厂房扩建项目 | 15,000.00 | 实施中 | 关于上海赛伦生物技术股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 方正证券承销保荐有限责任公司（以下简称"保荐机构"）作为上海赛伦生 物技术股份有限公司（以下简称"公司"或"赛伦生物"）首次公开发行股票并 在科创板上市的保荐机构及持续督导机构，根据《证券发行上市保荐业务管理办 法》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司 自律监管指引第 1 号—规范运作 ...

方正证券承销保荐有限责任公司 关于上海赛伦生物技术股份有限公司使用自有资金 支付募投项目人员费用并以募集资金等额置换的核查意见 方正证券承销保荐有限责任公司（以下简称"保荐机构"）作为上海赛伦生 物技术股份有限公司（以下简称"公司"或"赛伦生物"）首次公开发行股票并 在科创板上市的保荐机构及持续督导机构，根据《上海证券交易所科创板股票上 市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号—规范运作》《上 市公司募集资金监管规则》等法律法规及业务规则的规定，就赛伦生物使用自有 资金支付募投项目人员费用并以募集资金等额置换事项进行了核查，具体情况如 下： 一、募集资金基本情况 公司已按规定对募集资金采取了专户存储制度，设立了相关募集资金专项账 户。募集资金到账后，已全部存放于募集资金专项账户内，公司已与保荐机构、 存放募集资金的银行签署了《募集资金专户存储三方监管协议》。 根据中国证券监督管理委员会《关于同意上海赛伦生物技术股份有限公司首 次公开发行股票注册的批复》（证监许可[2022]204 号）的批准，公司获准向社 会公开发行人民币普通股 2,706 万股，每股面值为 1.00 元，每股发行价格为 ...

证券代码：688163 证券简称：赛伦生物 公告编号：2026-003 上海赛伦生物技术股份有限公司 关于使用自有资金支付募投项目人员费用 并以募集资金等额置换的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海赛伦生物技术股份有限公司（以下简称"公司"）于 2026 年 3 月 20 日 召开第四届董事会第十次会议，审议通过了《关于使用自有资金支付募投项目人 员费用并以募集资金等额置换的议案》，同意公司在募投项目实施期间，根据实 际需要，先行使用自有资金支付募投项目人员费用，后续定期从募集资金专户划 转等额资金至公司自有资金账户进行置换，该部分等额置换资金视同募投项目使 用资金，上述事项无需提交公司股东会审议。保荐机构方正证券承销保荐有限责 任公司对本事项出具了明确的核查意见。现将具体情况公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意上海赛伦生物技术股份有限公司首 次公开发行股票注册的批复》（证监许可【2022】204 号）的批准，公司获准向 社会公开发行人民币普通股 2,706 万股，每 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海赛伦生物技术股份有限公司（以下简称"赛伦生物"或"公司"）第四 届董事会第十次会议审议通过了《关于使用部分暂时闲置募集资金进行现金管理 的议案》，同意在保证不影响公司募集资金投资计划正常进行的前提下，使用最 高不超过人民币 5 亿元的暂时闲置募集资金进行现金管理，用于购买安全性高、 流动性好、有保本约定的投资产品（包括但不限于结构性存款、协定存款、通知 存款、定期存款、大额存单、收益凭证等），期限不超过 12 个月，自董事会审议 通过之日起 12 个月内有效。在上述额度及期限范围内，公司可以循环滚动使用。 公司董事会授权公司管理层在决议有效期、上述投资额度、投资期限及投资品种 内，行使投资决策权并签署相关法律文件，具体事项由公司财务部负责实施。保 荐机构方正证券承销保荐有限责任公司对本事项出具了明确的核查意见。上述事 项无需提交股东会审议，现将相关情况公告如下： 一、募集资金基本情况 根据中国证券监督管理委员会《关于同意上海赛伦生物技术股份有限公司首 次公开发行股票注册的 ...

Core Viewpoint - The company has received acceptance for its new drug application for antivenom serum targeting bee venom, but currently has no plans to expand its antitoxin technology platform to other animal toxins such as scorpion or spider venom [1] Group 1 - The company confirmed its focus on developing new drug projects specifically for antivenom against bee and snake venom toxins [1] - There are no ongoing new drug projects related to other animal toxins at this time [1] - The company will disclose any officially launched new drug research projects in its regular reports [1]

Financial Data Summary - The company reported total revenue of 196.21 million RMB, a year-on-year increase of 0.66% [2] - Operating profit reached 62.04 million RMB, reflecting a growth of 19.34% compared to the previous year [2] - Total profit amounted to 61.74 million RMB, showing a year-on-year increase of 22.10% [2] - Net profit attributable to the parent company was 51.71 million RMB, up 16.76% year-on-year [2] - Net profit attributable to the parent company after deducting non-recurring gains and losses was 42.56 million RMB, with a significant increase of 50.65% [2][5] Financial Position - As of the end of the reporting period, total assets were 1.16 billion RMB, an increase of 3.83% from the beginning of the period [3] - Equity attributable to the parent company was 1.11 billion RMB, which is a 1.56% increase from the beginning of the period [3] Factors Influencing Performance - The slight increase in revenue was attributed to the initial sales phase of the rabies serum launched in the second half of 2025, which did not contribute significantly to revenue during the reporting period [4] - The growth in net profit was primarily due to the reduction of investment losses recognized from the associated company, Shanghai Saiyuan Biotechnology Co., Ltd., and a decrease in non-recurring gains and losses, as well as a reduction in R&D expenses [4]

Group 1 - The company, Sairun Bio, announced that it expects to achieve total operating revenue of 196.21 million yuan in 2025, representing a year-on-year growth of 0.66% [2] - The net profit attributable to the parent company is projected to be 51.71 million yuan, reflecting a year-on-year increase of 16.76% [2]

Core Viewpoint - Sirun Biotech (688163.SH) reported a slight increase in total revenue for 2025, with a net profit growth attributed to various factors including reduced R&D expenses and changes in investment valuations [1] Financial Performance - The total revenue for 2025 reached 196 million yuan, representing a year-on-year growth of 0.66% [1] - The net profit attributable to the parent company was 51.71 million yuan, showing a year-on-year increase of 16.76% [1] - The gross profit margin remained stable, indicating consistent profitability despite the modest revenue growth [1] Product Development - The anti-rabies serum launched in the second half of 2025 is still in the early stages of sales and has not yet made a significant contribution to revenue during the reporting period [1] Investment and Financial Adjustments - The increase in net profit was primarily due to the recognition of investment losses in the joint venture Shanghai Saiyuan Biotech Co., Ltd. in 2024, along with full impairment provisions for long-term equity investments [1] - There was a decrease in non-recurring gains and losses compared to the previous period, contributing to the overall profit increase [1] - R&D expenses also saw a year-on-year reduction, further supporting the profit growth [1]

Core Viewpoint - Sirun Biologics (688163.SH) reported a slight increase in total revenue for the fiscal year 2025, with a notable growth in net profit driven by various factors including reduced non-recurring losses and lower R&D expenses [1] Financial Performance - The company achieved total operating revenue of 196.21 million yuan, representing a year-on-year increase of 0.66% [1] - Operating profit reached 62.04 million yuan, up 19.34% year-on-year [1] - Total profit amounted to 61.74 million yuan, reflecting a year-on-year growth of 22.10% [1] - Net profit attributable to shareholders was 51.71 million yuan, showing a year-on-year increase of 16.76% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 42.56 million yuan, which is a significant increase of 50.65% year-on-year [1] Revenue and Market Contribution - The company's revenue showed a slight increase, while the gross profit margin remained stable [1] - The anti-rabies serum, which was listed in the second half of 2025, has not yet made a significant contribution to revenue during the reporting period [1] Factors Influencing Profit Growth - The increase in net profit is primarily attributed to the recognition of investment losses in the associate company Shanghai Saiyuan Biotechnology Co., Ltd. in 2024, full impairment of long-term equity investment balances, a decrease in non-recurring gains and losses, and a reduction in R&D expenses [1]

Financial Performance - Total revenue for 2025 reached RMB 196.21 million, a year-on-year increase of 0.66%[5] - Operating profit was RMB 62.04 million, reflecting a growth of 19.34% compared to the previous year[5] - Net profit attributable to shareholders of the parent company was RMB 51.71 million, up 16.76% year-on-year[5] - Net profit excluding non-recurring gains and losses increased by 50.65% to RMB 42.56 million[8] - Basic earnings per share rose to RMB 0.48, an increase of 17.07%[3] Assets and Equity - Total assets at the end of the reporting period were RMB 1,162.94 million, a 3.83% increase from the beginning of the period[6] - Equity attributable to shareholders of the parent company was RMB 1,112.58 million, up 1.56%[6] Profitability and Growth Factors - The company’s gross profit margin remained stable despite a slight increase in revenue[7] - The launch of the anti-rabies serum in the second half of 2025 is expected to contribute to future revenue growth[7] - The company has noted a decrease in non-recurring gains and losses, primarily due to reduced investment income from structured deposits and government subsidies[8]